Biotech

All Articles

Kairos goes public with $6M IPO to finance trials of cancer cells medication

.Along with a triad of biotechs striking the Nasdaq on Friday, it was actually easy to miss a smalle...

Vaccine and Keytruda combination helpful in squamous cell carcinoma

.Immune checkpoint preventions are actually the superheroes of cancer cells therapy. Medicines like ...

Cue Biopharma queues up J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of significant management hirings, firings a...

Regeneron's Opdualag opponent shows 57% action cost

.Regeneron is actually back along with long-term follow-up for its LAG-3 inhibitor and PD-1 inhibito...

AstraZeneca messages records on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has shared an early consider the performance of its own in-house antibody-drug conjugat...

iTeos- GSK's TIGIT star shows significant remodeling

.After declaring a phase 3 launch based on positive midstage outcomes, iTeos and GSK are ultimately ...

More collaborative FDA may accelerate uncommon illness R&ampD: record

.The FDA needs to be much more open and joint to let loose a surge in commendations of rare ailment ...

Zenas, MBX, Bicara head to Nasdaq in warm time for biotech IPOs

.It's an extraordinarily active Friday for biotech IPOs, along with Zenas BioPharma, MBX as well as ...

Atea's COVID antiviral neglects to stop hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has stopped working an additional COVID-19 trial, yet the biotech s...

Neurocrine's bid to spare schizophrenia prospect neglects

.Neurocrine Biosciences' schizophrenia program pivot has actually stopped working. The biotech was a...